维吾尔族妇女宫颈鳞癌早期患者血浆低丰度蛋白质组差异图谱的二维液相色谱分析

Analysis of low abundant plasma proteome profile specific to early stage cervical cancer in Uighur women by two-dimentionalliquid phase chromatography

目的:依托蛋白质二维液相色谱技术,建立维吾尔族妇女宫颈鳞癌早期患者特异性血浆低丰度蛋白质组图谱鉴别模型。方法:收集维吾尔族妇女血浆标本共48例,临床分期为Ⅰ～Ⅱa的宫颈鳞癌早期患者26例,慢性宫颈炎患者22例。分别制备血浆低丰度蛋白质组样品并通过蛋白质二维液相色谱系统(ProteomeLah^(TM)PF-2D)分离与鉴别分析。结果:确定了宫颈炎和早期宫颈鳞癌患者的基于蛋白质等电点和疏水性特征的血浆低丰度蛋白质组图谱,筛选出9个差异表达明显的蛋白位点,在宫颈鳞癌早期患者血浆中8个低丰度蛋白组分含量明显上升,1个组分含量下降。结论:建立了宫颈癌早期患者特异性血浆蛋白质组差异图谱鉴别模型,提示二维液相色谱技术作为一种高通量技术手段在血浆蛋白质组学研究中有很大的应用潜力。

OBJECTIVE：To analyze fingerprint features of low abundant plasma proteome specific to early stage cervical squamous cell carcinoma in Uighur women by two dimensional liquid phase chromatography,for establishment of a plasma proteomic model to distinguish patients with early cancer from the normal.METHODS：We collected 48 plasma samples from Uighur women including 26 cases of early stage cancer at clinical stageⅠ-Ⅱa and 22 cases of cervicitis.After preparation of low abundant plasma proteome by depletion of high abundant plasma proteins,the proteomic fingerprint features of patients with early stage cancer and cervicitis were analysed by separation and analysis of the plasma proteome with two dimensional liquid phase chromatography and subsequent data processing with professional softwares,to establish a differentiating model of plasma proteome for patients with early stage cancer.RESULTS：By setting up the difference of protein content of two or more as a standard for quantitative differences,we found up to 8 peaks with increased and 1 with reduced protein content in patients with early stage of cancer compared to cervicitis. CONCLUSION：The features of low abundant plasma proteome specific to patients with early stage cancer were established.The two-dimensional liquid phase chromatography as high throughput method has a high potential in the research of plasma proteomics.The marked differences in low abundant plasma proteomes between early stage cervical cancer and cervicitis in Uighur women may provide important evidence for the identification of plasma protein markers of the cancer development and early diagnosis in the future.